Vivos Therapeutics, Inc. (VVOS)
Market Cap | 30.84M |
Revenue (ttm) | 14.39M |
Net Income (ttm) | -14.32M |
Shares Out | 7.50M |
EPS (ttm) | -1.78 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 124,046 |
Open | 4.340 |
Previous Close | 4.400 |
Day's Range | 3.950 - 4.412 |
52-Week Range | 1.980 - 7.950 |
Beta | 6.99 |
Analysts | Strong Buy |
Price Target | 6.10 (+48.42%) |
Earnings Date | Aug 19, 2025 |
About VVOS
Vivos Therapeutics, Inc. operates as a medical technology company that develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. The company also offers VivoScore Program, a screening and home sleep test in adults and children. It markets and sells its appliances, and related t... [Read more]
Financial Performance
In 2024, Vivos Therapeutics's revenue was $15.03 million, an increase of 8.91% compared to the previous year's $13.80 million. Losses were -$11.14 million, -18.02% less than in 2023.
Financial StatementsAnalyst Summary
According to 2 analysts, the average rating for VVOS stock is "Strong Buy." The 12-month stock price target is $6.1, which is an increase of 48.42% from the latest price.
News

Vivos Therapeutics, Inc. (VVOS) Q2 2025 Earnings Call Transcript
Vivos Therapeutics, Inc. (NASDAQ:VVOS) Q2 2025 Earnings Conference Call August 19, 2025 5:00 PM ET Company Participants Bradford K. Amman - CFO, Treasurer & Secretary R.

Vivos Therapeutics Reports Second Quarter 2025 Financial Results and Provides Operational Update
Quarter highlighted by the key acquisition of The Sleep Center of Nevada, which is generating revenue and seeing strong patient demand for Vivos' differentiated array of highly effective OSA treatmen...

Vivos Therapeutics Schedules Release of Second Quarter 2025 Financial Results and Conference Call
LITTLETON, Colo., Aug. 19, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company'') (NASDAQ: VVOS), a leading medical device and technology company specializing in the development...

New Clinical Trial Data Published Showing Positive Results from Use of Vivos Technology to Treat Obstructive Sleep Apnea in Children
LITTLETON, Colo., June 26, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a leader in proprietary, non-invasive treatments for obstructive sleep apnea (OS...

Vivos Therapeutics, Inc. (VVOS) Q1 2025 Earnings Call Transcript
Vivos Therapeutics, Inc. (NASDAQ:VVOS) Q1 2025 Earnings Conference Call May 15, 2025 5:00 PM ET Company Participants Brad Amman - CFO Kirk Huntsman - Chairman and CEO Conference Call Participants Do ...

Vivos Therapeutics Schedules Release of First Quarter 2025 Financial Results and Conference Call
LITTLETON, Colo., May 14, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a leading medical device and technology company specializing in the development a...

Vivos Therapeutics Signs Definitive Agreement to Acquire Largest Sleep Center Operator in Nevada
By acquiring The Sleep Center of Nevada, Vivos expands its business model to make its OSA treatments available to thousands of patients in the greater Las Vegas metro area Acquisition expected to clos...

Vivos Therapeutics, Inc. (VVOS) Q4 2024 Earnings Call Transcript
Vivos Therapeutics, Inc. (NASDAQ:VVOS) Q4 2024 Earnings Conference Call March 31, 2025 5:00 PM ET Company Participants Bradford Amman - CFO, Treasurer & Secretary Kirk Huntsman - Co-Founder, Chairman...

Vivos Therapeutics Reports Full Year 2024 Financial Results and Provides Operational Update
Year over year product revenue increased 26% Operating expenses declined 21% and year over year operating loss decreased 35% Management to Host Conference Call today at 5:00 pm ET LITTLETON, Colo., Ma...

Vivos Therapeutics Schedules Release of Full Year 2024 Financial Results and Conference Call
LITTLETON, Colo., March 28, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a leading medical device and technology company specializing in the development...

Vivos Therapeutics Announces $3.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
LITTLETON, Colo., Dec. 23, 2024 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company'') (NASDAQ: VVOS), a leading medical device and technology company specializing in the development...

Vivos Therapeutics, Inc. (VVOS) Q3 2024 Earnings Call Transcript
Vivos Therapeutics, Inc. (NASDAQ:VVOS) Q3 2024 Earnings Conference Call November 14, 2024 5:00 PM ET Company Participants Kirk Huntsman - Chariman & CEO Brad Amman - CFO Conference Call Participants ...

Vivos Therapeutics Schedules Release of Third Quarter 2024 Financial Results and Conference Call
LITTLETON, Colo., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a leading medical device and technology company specializing in the development ...

Vivos Therapeutics Granted CPT® Coverage and Reimbursement Codes for All Vivos CARE Oral Medical Devices From American Medical Association
New Medical Codes will Facilitate Billing by Commercial Payers for Vivos CARE Treatment for Obstructive Sleep Apnea in Adults and Children New Medical Codes will Facilitate Billing by Commercial Payer...

Vivos Therapeutics Receives Groundbreaking FDA 510(k) Clearance to Treat Moderate to Severe Pediatric Sleep Apnea and Snoring
Vivos is poised to disrupt the very significant pediatric obstructive sleep apnea (OSA) market with new FDA clearance and new strategic marketing and distribution model

Vivos Therapeutics, Inc. (VVOS) Q2 2024 Earnings Call Transcript
Vivos Therapeutics, Inc. (NASDAQ:VVOS) Q2 2024 Earnings Conference Call August 14, 2024 5:00 PM ET Company Participants John Lee - Vivos' Executive Vice President of Marketing Kirk Huntsman - Chairma...

Vivos Therapeutics Reports Second Quarter 2024 Financial Results and Provides Operational Update
Revenue Increased 19% both Sequentially and Year over Year Operating Expenses Decreased 31%, Marking Eight Consecutive Quarters of Year Over Year Improvement Due to Successful Cost Cutting Initiatives...

Vivos Therapeutics Schedules Release of Second Quarter 2024 Financial Results and Conference Call
LITTLETON, Colo., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a leading medical device and technology company specializing in the development ...

Vivos Therapeutics Announces Positive Results From 7-Month Multi-Site Pilot of its New Provider-Based Marketing and Distribution Model
8 Out of 10 Newly Diagnosed OSA Patients Choose Oral Appliance Therapy Over CPAP and Preferred Vivos' Flagship CARE Oral Medical Devices 5 to 1 Over Traditional Oral Appliances 8 Out of 10 Newly Diagn...

Vivos Therapeutics Closes $7.5 Million At-The-Market Private Equity-Backed Investment and Launches Strategic Marketing and Distribution Alliance
Alliance with Sleep Treatment Provider in Colorado Marks Critical Pivot in Vivos' Marketing and Distribution Model Aimed at Enhancing Revenue Streams and Potential Profit

Vivos Therapeutics, Inc. (VVOS) Q1 2024 Earnings Call Transcript
Vivos Therapeutics, Inc. (NASDAQ:VVOS) Q1 2024 Results Conference Call May 14, 2024 5:00 PM ET Company Participants Julie Gannon - Investor Relations Officer Kirk Huntsman - Chairman & Chief Executiv...

Vivos Therapeutics Reports First Quarter 2024 Financial Results and Provides Operational Update
Vivos Expanding its Revenue Generating Initiatives As Operating Expenses Decrease 22%, Representing Seven Consecutive Quarters of Year Over Year Improvement Due to Successful Cost Cutting Initiatives

Vivos Therapeutics Schedules Release of First Quarter 2024 Financial Results and Conference Call
LITTLETON, Colo., May 14, 2024 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a leading medical device and technology company specializing in the development a...

Vivos Therapeutics' Flagship CARE Oral Medical Devices Receive Full Approval for Medicare Reimbursement
First Medicare-Accepted Oral Appliance Treatment for All Severities of Obstructive Sleep Apnea in Adults First Medicare-Accepted Oral Appliance Treatment for All Severities of Obstructive Sleep Apnea ...

Vivos Therapeutics, Inc. (VVOS) Q4 2023 Earnings Call Transcript
Vivos Therapeutics, Inc. (VVOS) Q4 2023 Earnings Call Transcript